Study Title: A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
For more information about the trial above please contact the study team:Medical University of South CarolinaAffiliate Principal Investigator, Lupak, Oleksandra, at lupak@musc.edu.Principal Investigator, Rangel, Christopher, at rangelc@musc.edu.Study Coordinator, Shealor, Jessica, at shealorj@musc.edu.Ralph H. Johnson VAMCStudy Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov.Trial opened at the following institutions: Medical University of South Carolina, Ralph H. Johnson VAMC